Dysexecutive Syndrome A Specific Pattern of Cognitive Impairment in Systemic Sclerosis PDF Print E-mail
Sunday, 07 July 2013 20:31
Systemic sclerosis (SSc), also called scleroderma, is a connective-tissue disorder characterized by obliterative microvascular lesions and diffuse interstitial fibrosis. SSc damages the small and medium-sized vessels serving the skin, joints (especially fingers and toes), and internal organs such as the lungs, gastrointestinal tract, kidneys, and heart. In most patients, neurological involvement is limited, and localized to the peripheral nervous system. Raynaud phenomenon (RP) is a prominent early vascular feature of SSc, affecting 90% of patients during their disease course and, in some, progressing
to severe ischemia.

Although the typical manifestation of neurological involvement in SSc is mononeuropathy or polyneuropathy, some imaging studies have reported cerebral hypoperfusion and acute cerebral vasculitis. Cognitive dysfunction is one of the important signs of neurological involvement in systemic lupus erythematosus, affecting up to 80% of patients. In most, the cognitive dysfunction is attributed to RP or antiphospholipid antibodies.

Although RP is a well-known feature of SSc, little is known about cognitive functioning in SSc. Limited data from small series suggest possible impairment. In our study, we aimed to evaluate cognitive functioning in patients with SSc who had no manifest sign of neurological involvement and to determine whether they showed a specific pattern of cognitive impairment that might be caused by cerebral hypoperfusion.

To continue reading the full study, please download from the link provided below.

 
More articles :

» Long-Term Outcomes of Scleroderma Renal Crisis

Virginia D. Steen, MD, and Thomas A. Medsger Jr., MDPublished: October 17th, 2000

» Scleroderma in Children: Emerging Management Issues

Saumya PandaDepartment of Dermatology, KPC Medical College, Kolkata, IndiaDate of Web Publication: 21-Jul-2010Abstract         Scleroderma is a set of rare connective tissue diseases of unknown etiology. It is...

» Ryan Roy Racing to Raise Awareness of Scleroderma

Ryan Roy, of Bellingham, Wash., only has been doing triathlons for two years. In 2010, he completed three races at sprint and Olympic distances. For 2011, in addition to competing in sprint and Olympic triathlons, and his first half marathon in...

» Testing New Drugs for Early Diffuse Systemic Sclerosis

For patients with the connective tissue disease known as Systemic Sclerosis or – there are few reliable drug treatments. There has been emerging interest in the potential of a class of drugs called (TKI) to ameliorate a major feature of the...

» Top 10 Scleroderma Stories For 2012

For the hundreds of thousands of people around the world, living with Scleroderma can be particularly challenging. As part of the Foundation's ongoing mission, we seek to source and provide useful information, tips, and articles which can help...

» Apoptosis Modulation as a Promising Target for Treatment of Systemic Sclerosis

St´ephane Chabaud and V´eronique J. MoulinReceived 1 June 2011; Revised 6 July 2011; Accepted 6 July 2011Systemic sclerosis (scleroderma, SSc) is a heterogeneous disease which develops into three forms: limited, intermediate, and diffuse. The...